Human Immunodeficiency Virus Clinical Trial
Official title:
An Innovative Telephone Intervention for HIV-Positive Smokers
The goal of this research study is to look at treatments that may help individuals who have HIV/AIDS to stop smoking.
If you agree to take part in this study, researchers will first do a test to learn what the
CO level of your blood is. To do this test, you will be asked to blow into a cardboard tube.
If the test finds that you are ineligible, you will not be able to continue on this study.
If you are found to be eligible, you will be enrolled in this study and asked to complete an
interview that should last about 1 hour. During this interview, you will be asked basic
questions, such as your age, education level, and smoking history. You will also be asked
questions about your mood, quality of life, and stress. You will then be asked to complete a
short test that involves completing some basic tasks, such as remembering several words and
drawing a simple shape. This test, which will take about 2-5 minutes to complete, is used to
measure attention and concentration.
You will then be randomly assigned (as in the toss of a coin) to one of two treatment
groups. There is an equal chance of being assigned to either group.
If you are assigned to Group 1, you will receive advice from your physician/provider to stop
smoking and written materials designed to help you quit smoking.
If you are assigned to Group 2, you will receive the advice from your physician/provider to
quit smoking and the written materials, but you also be given a cell phone and be called 11
times over the course of an 12 to 13 week period. During these calls, which will last about
10 minutes, you will be asked to talk about smoking and quitting smoking. Access to a
hotline number that you can call to speak with a counselor about quitting smoking will also
be given to you if you are assigned to group 2. Participants in Group 1 will not get the
number to the hotline. There is a limited number of prepaid minutes on the phone, so
participants who receive a cell phone should make an effort to save enough minutes to
complete this study.
You will be asked to complete three more interviews about 3-, 6-, and 12-months after the
first interview. During these interviews, you will again be asked questions about your
smoking behavior, mood, quality of life, and stress. All three of these interviews will take
about one hour to complete. Your participation in this study will be complete after the
12-month interview.
Lost, stolen, or broken cell phones will not be replaced, but participants will remain on
study.
This is an investigational study. Up to 705 participants will take part in this research
study. All participants will be enrolled at Thomas Street Clinic.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03516318 -
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
|
N/A | |
Completed |
NCT04653194 -
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
|
Phase 3 | |
Completed |
NCT01792570 -
DRV/r + RPV QD: Efficacy and Toxicity Reduction
|
Phase 3 | |
Active, not recruiting |
NCT04826562 -
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
|
Phase 4 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Completed |
NCT02812329 -
Intervention to Encourage HIV Testing and Counseling Among Adolescents
|
Phase 1 | |
Completed |
NCT02919306 -
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
|
Phase 1/Phase 2 | |
Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
Completed |
NCT01944371 -
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01778374 -
Mater-Bronx Rapid HIV Testing Project.
|
N/A | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT01460433 -
Problems With Immune Recovery in the Gut Tissue
|
N/A | |
Completed |
NCT01490346 -
Tissue Drug Levels of HIV Medications
|
N/A | |
Completed |
NCT01076179 -
Kaletra in Combination With Antiretroviral Agents
|
N/A | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Terminated |
NCT04240210 -
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
|
Phase 4 | |
Active, not recruiting |
NCT04704336 -
Integration of Hypertension Management Into HIV Care in Nigeria
|
N/A | |
Completed |
NCT03254277 -
3BNC117-LS First-in-Human Phase 1 Study
|
Phase 1 |